4.8(top 5%)
impact factor
6.3K(top 5%)
papers
182.1K(top 2%)
citations
141(top 5%)
h-index
4.9(top 5%)
impact factor
6.8K
all documents
192.2K
doc citations
205(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy20071,104
2Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy20091,089
3An immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunology, Immunotherapy2012703
4Tumor antigen-specific T helper cells in cancer immunity and immunotherapyCancer Immunology, Immunotherapy2005609
5Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapyCancer Immunology, Immunotherapy2005509
6Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13Cancer Immunology, Immunotherapy2011506
7Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumabCancer Immunology, Immunotherapy2014472
8Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunityCancer Immunology, Immunotherapy2010470
9Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodiesCancer Immunology, Immunotherapy1993448
10Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatmentCancer Immunology, Immunotherapy2009436
11A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy2005428
12A listing of human tumor antigens recognized by T cellsCancer Immunology, Immunotherapy2001426
13Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancerCancer Immunology, Immunotherapy2014423
14Apoptosis pathways in cancer and cancer therapyCancer Immunology, Immunotherapy2004420
15Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancersCancer Immunology, Immunotherapy2007413
16Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasionCancer Immunology, Immunotherapy2007412
17Signaling events involved in anti-CD20-induced apoptosis of malignant human B cellsCancer Immunology, Immunotherapy2000380
18Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer Immunology, Immunotherapy2014374
19The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cellsCancer Immunology, Immunotherapy2009362
20Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancerCancer Immunology, Immunotherapy2009347
21Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytesCancer Immunology, Immunotherapy2006341
22Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncologyCancer Immunology, Immunotherapy2012340
23Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In CancerCancer Immunology, Immunotherapy2006323
24Derangement of immune responses by myeloid suppressor cellsCancer Immunology, Immunotherapy2004321
25Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunology, Immunotherapy2013320
262011: the immune hallmarks of cancerCancer Immunology, Immunotherapy2011316
27Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR NanobodiesCancer Immunology, Immunotherapy2007315
28Quantifying tumor-infiltrating immune cells from transcriptomics dataCancer Immunology, Immunotherapy2018292
29Immature myeloid cells and cancer-associated immune suppressionCancer Immunology, Immunotherapy2002289
30IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolismCancer Immunology, Immunotherapy2009281
31Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progressionCancer Immunology, Immunotherapy2013281
32Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancerCancer Immunology, Immunotherapy2011280
33Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy2010279
34Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCancer Immunology, Immunotherapy2006278
35Immunotherapy of cancer with dendritic-cell-based vaccinesCancer Immunology, Immunotherapy1998277
36Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cellsCancer Immunology, Immunotherapy2001273
37The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patientsCancer Immunology, Immunotherapy2008271
38The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityCancer Immunology, Immunotherapy2017271
39Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancerCancer Immunology, Immunotherapy2013268
40CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancersCancer Immunology, Immunotherapy2006265
41Regulation of immunity and oncogenesis by the IRF transcription factor familyCancer Immunology, Immunotherapy2010265
42Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCCCancer Immunology, Immunotherapy2013258
43Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaCancer Immunology, Immunotherapy2014253
44PD-1 and PD-L1 antibodies in cancer: current status and future directionsCancer Immunology, Immunotherapy2017253
45Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient casesCancer Immunology, Immunotherapy2009246
46Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulinCancer Immunology, Immunotherapy2012246
47Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of “heat-controlled necrosis” with heat shock protein expressionCancer Immunology, Immunotherapy2006245
48A systematic review of humoral immune responses against tumor antigensCancer Immunology, Immunotherapy2009245
49Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growthCancer Immunology, Immunotherapy2012242
50The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escapeCancer Immunology, Immunotherapy2004239